Cargando…

Preoperative HE4, CA125 and ROMA in the differential diagnosis of benign and malignant adnexal masses

BACKGROUND: The aim of this study was to evaluate HE4, CA125 and ROMA in the preoperative differentiation benign ovarian diseases from epithelial ovarian cancer depending on the menopausal status. METHODS: In order to estimate markers’ concentrations in the serum of women with benign ovarian disease...

Descripción completa

Detalles Bibliográficos
Autores principales:	Terlikowska, Katarzyna M., Dobrzycka, Bozena, Witkowska, Anna M., Mackowiak-Matejczyk, Beata, Sledziewski, Tomasz Kamil, Kinalski, Maciej, Terlikowski, Slawomir J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4952144/ https://www.ncbi.nlm.nih.gov/pubmed/27436085 http://dx.doi.org/10.1186/s13048-016-0254-7

Ejemplares similares

Prognostic significance of pretreatment VEGF, survivin, and Smac/DIABLO serum levels in patients with serous ovarian carcinoma
por: Dobrzycka, Bozena, et al.
Publicado: (2015)

Clinical value of selected markers of angiogenesis, inflammation, insulin resistance and obesity in type 1 endometrial cancer
por: Terlikowska, Katarzyna M., et al.
Publicado: (2020)

Transvaginal electrical stimulation with surface-EMG biofeedback in managing stress urinary incontinence in women of premenopausal age: a double-blind, placebo-controlled, randomized clinical trial
por: Terlikowski, Robert, et al.
Publicado: (2013)

Comparison of HE4, CA125, ROMA and CPH-I for Preoperative Assessment of Adnexal Tumors
por: Carreras-Dieguez, Núria, et al.
Publicado: (2022)

Chimeric Antigen Receptor Design and Efficacy in Ovarian Cancer Treatment
por: Terlikowska, Katarzyna M., et al.
Publicado: (2021)

Potential Application of Curcumin and Its Analogues in the Treatment Strategy of Patients with Primary Epithelial Ovarian Cancer
por: Terlikowska, Katarzyna M., et al.
Publicado: (2014)

Performance of IOTA Simple Rules Risks, ADNEX Model, Subjective Assessment Compared to CA125 and HE4 with ROMA Algorithm in Discriminating between Benign, Borderline and Stage I Malignant Adnexal Lesions
por: Czekierdowski, Artur, et al.
Publicado: (2023)

Standard and optimal cut-off values of serum ca-125, HE4 and ROMA in preoperative prediction of ovarian cancer in Vietnam
por: Huy, Nguyen Vu Quoc, et al.
Publicado: (2018)

The diagnostic value of serum HE4 and CA-125 and ROMA index in ovarian cancer
por: WEI, SU, et al.
Publicado: (2016)

Are ROMA and HE4 More Accurate than CA-125, in Predicting of Ovarian Epithelial Carcinoma?
por: Behnamfar, Fariba, et al.
Publicado: (2023)

Preoperative HE4 and ROMA values do not improve the CA125 diagnostic value for borderline tumors of the ovary (BOT) – a study of the TOC Consortium
por: Braicu, Elena Ioana, et al.
Publicado: (2014)

Biomarkers and algorithms for diagnosis of ovarian cancer: CA125, HE4, RMI and ROMA, a review
por: Dochez, Vincent, et al.
Publicado: (2019)

Comparison of the diagnostic accuracy of HE4 with CA125 and validation of the ROMA index in differentiating malignant and benign epithelial ovarian tumours among patients in Lagos, Nigeria
por: Shittu, Khadijah Adebisi, et al.
Publicado: (2023)

Adnexal mass with extremely high levels of CA-125 and CA19-9 but normal Human Epididymis Protein 4 (HE4) and Risk of Ovarian Malignancy Algorithm (ROMA): Endometriosis or ovarian malignancy? A case report
por: Khodaverdi, Sepideh, et al.
Publicado: (2018)

Efficacy of IOTA simple rules, O-RADS, and CA125 to distinguish benign and malignant adnexal masses
por: Xie, Wen ting, et al.
Publicado: (2022)

HE4 a novel tumour marker for ovarian cancer: comparison with CA 125 and ROMA algorithm in patients with gynaecological diseases
por: Molina, Rafael, et al.
Publicado: (2011)

Assessment of Diagnostic Values among CA-125, RMI, HE4, and ROMA for Cancer Prediction in Women with Nonfunctional Ovarian Cysts
por: Oranratanaphan, Shina, et al.
Publicado: (2018)

Diagnostic Performance of F-18 FDG PET/CT Compared with CA125, HE4, and ROMA for Epithelial Ovarian Cancer
por: Lee, Sun Seong, et al.
Publicado: (2021)

Comparison of HE4, CA125, and ROMA Diagnostic Accuracy: A Prospective and Multicenter Study for Chinese Women With Epithelial Ovarian Cancer
por: Zhang, Pengjun, et al.
Publicado: (2015)

A comparison of CA125, HE4, risk ovarian malignancy algorithm (ROMA), and risk malignancy index (RMI) for the classification of ovarian masses
por: Anton, Cristina, et al.
Publicado: (2012)

Adnexal Masses Suspected to Be Benign Treated with Laparoscopy
por: Demir, Richard H., et al.
Publicado: (2012)

Practical Recommendations for the Management of Benign Adnexal Masses
por: Rocha, Rodrigo Manieri, et al.
Publicado: (2020)

Can Replacing CA125 with HE4 in Risk of Malignancy Indices 1–4 Improve Diagnostic Performance in the Presurgical Assessment of Adnexal Tumors?
por: Abdalla, Nabil, et al.
Publicado: (2017)

The Use of Human Epididymis 4 and Cancer Antigen 125 Tumor Markers in the Benign or Malignant Differential Diagnosis of Pelvic or Adnexal Masses
por: Dolgun, Zehra Nihal, et al.
Publicado: (2017)

Evaluation of Probably Benign Adnexal Masses in Postmenopausal Women
por: Karakaya, Burcu Kisa, et al.
Publicado: (2017)

Diagnostic Value of Preoperative CA125, LDH and HE4 for Leiomyosarcoma of the Female Reproductive System
por: Zhang, Fenfen, et al.
Publicado: (2021)

M-CSF in a new biomarker panel with HE4 and CA 125 in the diagnostics of epithelial ovarian cancer patients
por: Będkowska, Grażyna Ewa, et al.
Publicado: (2015)

Does the Risk of Ovarian Malignancy Algorithm Provide Better Diagnostic Performance Than HE4 and CA125 in the Presurgical Differentiation of Adnexal Tumors in Polish Women?
por: Abdalla, Nabil, et al.
Publicado: (2018)

Serum HE4 and diagnosis of ovarian cancer in postmenopausal women with adnexal masses
por: Gentry-Maharaj, Aleksandra, et al.
Publicado: (2020)

Symptoms, CA125 and HE4 for the preoperative prediction of ovarian malignancy in Brazilian women with ovarian masses
por: Pitta, Denise da Rocha, et al.
Publicado: (2013)

Comparison of Ultrasound and Tumor Marker CA125 in Diagnosis of Adnexal Mass Malignancies
por: Behnamfar, Fariba, et al.
Publicado: (2022)

Diagnostic value of the gynecology imaging reporting and data system (GI-RADS) with the ovarian malignancy marker CA-125 in preoperative adnexal tumor assessment
por: Migda, Michal, et al.
Publicado: (2018)

Conservative Management of Asymptomatic Adnexal Masses Classified as Benign by the IOTA ADNEX Model: A Prospective Multicenter Portuguese Study
por: Brito, Marta Espanhol, et al.
Publicado: (2021)

The plasma concentration of VEGF, HE4 and CA125 as a new biomarkers panel in different stages and sub-types of epithelial ovarian tumors
por: Ławicki, Sławomir, et al.
Publicado: (2013)

Diagnostic value of CA125, HE4, and systemic immune-inflammation index in the preoperative investigation of ovarian masses
por: Song, Liyun, et al.
Publicado: (2023)

A Dual Biomarker TK1 Protein and CA125 or HE4-Based Algorithm as a Better Diagnostic Tool than ROMA Index in Early Detection of Ovarian Cancer
por: Cviič, Diana, et al.
Publicado: (2023)

Microcystic Adnexal Carcinoma Misdiagnosed as Desmoplastic Trichoepithelioma on Preoperative Biopsy
por: Koh, Sung Hoon, et al.
Publicado: (2015)

Preoperative Neutrophil Lymphocyte Ratio in Prediction of Adnexal Mass Torsion
por: Ghimire, Asmita, et al.
Publicado: (2023)

Benign vs. Malignant Skin Adnexal Neoplasms: How Useful are Silhouettes?
por: Tirumalae, Rajalakshmi, et al.
Publicado: (2013)

Microcystic adnexal carcinoma of the upper lip misdiagnosed benign desmoplastic trichoepithelioma
por: Rustemeyer, Jan, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_vcdkjd7c8032u9vph6dn14o4mb